Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study

被引：0
作者：
Xinguang Wang
Zhaoqing Fan
Xing Wang
Yingjian He
Yiqiang Liu
Xiang Wang
Bailin Zhang
Zefei Jiang
Tao Wang
Zhigang Yu
Fei Wang
Yinhua Liu
Yanping Li
Jianguo Zhang
Bin Luo
Hongchuan Jiang
Tianfeng Wang
Yuntao Xie
Jinfeng Li
Tao Ouyang
机构：
[1] Peking University Cancer Hospital & Institute,Breast Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Peking University Cancer Hospital & Institute,Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Breast Surgical Oncology
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Oncology
[5] The Fifth Medical Center of PLA General Hospital,Department of Breast Surgery, Cheeloo College of Medicine, The Second Hospital
[6] Shandong University,Breast Disease Center
[7] Peking University First Hospital,Department of Breast Surgery, Beijing Shijitan Hospital
[8] Capital Medical University,Department of Breast Surgery
[9] The Second Hospital of Harbin Medical University,Department of General Surgery, Clinical School of Medicine, Tsinghua Changgung Hospital
[10] Tsinghua University,Department of Breast Surgery, Beijing Chao Yang Hospital
[11] Capital Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 195卷
关键词：
Neoadjuvant endocrine therapy; Breast cancer; Pathological response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 464 条
  • [1] Parker JS(2009)Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160-1167
  • [2] Mullins M(1982)Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study Br Med J (Clin Res Ed) 284 869-870
  • [3] Cheang MC(2016)Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-1486
  • [4] Leung S(2011)Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031 J Clin Oncol 29 2342-2349
  • [5] Voduc D(2001)Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527-1532
  • [6] Vickery T(2005)Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108-5116
  • [7] Davies S(2001)Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial J Clin Oncol 19 3808-3816
  • [8] Fauron C(2021)Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: a systematic review and meta-analysis Breast 58 113-120
  • [9] He X(2007)The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329-2334
  • [10] Hu Z(2014)Pathologic complete response and long-term clinical beneft in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
12345678910